Rosetta Capital leads $66m Series B for Novimmune


drug-pharma-medical-healthcareLondon-based venture investor Rosetta Capital has led a CHF60m ($66m) Series B financing round for drug maker Novimmune.

Rosetta partner and co-founder Jonathan Hepple has joined the company’s board of directors to bring his 15 years of experience in the life sciences industry to bear on the business.

Novimmune CEO Jack Barbut said, “We welcome Rosetta as a new investor in Novimmune and look forward to working with Jonathan as a new member of our Board.

“His experience across orphan disease and protein engineering companies, and in the investment sector, nicely complements Novimmune’s other Board members’ perspectives.”

Last April Rosetta held a €30m final close for its latest fund aimed at picking up portfolio companies in direct secondary deals.

The venture capital investor picked up the commitments from eight LPs according to a US securities filing, which showed Bluetower Associates acted as a placement agent for Rosetta Capital IV.

Copyright © 2014 AltAssets